Active Ingredient: Encorafenib
Encorafenib in combination with cetuximab is indicated for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, who have received prior systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Oral, 300 milligrams encorafenib, once daily.
The recommended dose of encorafenib is 300 mg once daily, when used in combination with cetuximab.
Treatment should continue until the patient no longer derives benefit or the development of unacceptable toxicity.
If a dose of encorafenib is missed, the patient should only take the missed dose if it is more than 12 hours until the next scheduled dose.
In case of vomiting after administration of encorafenib, the patient should not take an additional dose and should take the next scheduled dose.
They may be taken with or without food. The concomitant administration of encorafenib with grapefruit juice should be avoided.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
